Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones, dentist network expansion, and royalty streams in Vivos Therapeutics filings can feel like navigating medical jargon and legalese at once. Whether you are searching for “Vivos Therapeutics insider trading Form 4 transactions” before earnings or just wondering how the latest 8-K affects competitive positioning, the details are scattered across hundreds of pages.
Stock Titan resolves that pain. Our platform delivers AI-powered summaries that translate dense disclosures into clear insights, then ties every data point back to what moves VVOS shares. Need the “Vivos Therapeutics quarterly earnings report 10-Q filing” distilled into key revenue shifts? Looking for “Vivos Therapeutics annual report 10-K simplified” to see R&D spend or FDA regulatory pathways? We surface it instantly, alongside
- real-time alerts for “Vivos Therapeutics Form 4 insider transactions real-time”
- side-by-side comparisons of each “Vivos Therapeutics proxy statement executive compensation”
- concise breakdowns of “Vivos Therapeutics 8-K material events explained”
Here you will find every form the company submits—10-K, 10-Q, 8-K, S-1, Section 16 filings—plus AI commentary that answers the exact questions professionals ask, like “understanding Vivos Therapeutics SEC documents with AI” or seeking a quick “Vivos Therapeutics earnings report filing analysis.” Monitor “Vivos Therapeutics executive stock transactions Form 4,” follow segment revenue trends, and assess how new clinical data may reshape growth projections, all without wading through technical text. Complex filings, made clear—so you can focus on decision-making, not document hunting.
Vivos Therapeutics filed a prospectus supplement updating its at-the-market program under its Form S-3. The company may offer and sell common stock with an aggregate offering price of up to $3,583,686 from time to time through H.C. Wainwright & Co., as sales agent, pursuant to General Instruction I.B.6 of Form S-3.
This update reflects current I.B.6 capacity and excludes approximately $4,605,773 of shares previously sold under the prior prospectus. The public float was approximately $35,068,378, calculated from 7,477,266 non‑affiliate shares at $4.69 per share as of August 26, 2025. Over the past 12 months, the company sold securities with an aggregate market value of approximately $8,105,774 under I.B.6. VVOS last traded at $2.97 on October 23, 2025.
Vivos Therapeutics (VVOS) reported that on October 24, 2025 it filed a prospectus supplement to increase the aggregate offering price of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., dated February 14, 2025. This update expands the capacity available for potential future issuances of common stock through the ATM program after effectiveness as permitted by the prospectus supplement.
The company also filed a legal opinion from Ellenoff Grossman & Schole LLP as Exhibit 5.1, with the related consent included in the same exhibit. VVOS’s common stock trades on The NASDAQ Stock Market LLC.
The filing is a Definitive Proxy Statement for Vivos Therapeutics, Inc. (VVOS) containing meeting and governance disclosures. Only stockholders of record as of September 8, 2025 may vote at the Annual Meeting. The board recommends FOR each director nominee in Proposal 1 and FOR Proposals 2 and 3. The company adopted a revised Insider Trading Policy to reflect changes to SEC Rule 10b5-1 effective February 2023, including pre-clearance by the Chief Financial Officer and specified trading windows. Beneficial ownership disclosures show V-CO Investors 2, LLC holds 828,000 shares (11.03%) and Dawei Luo holds 572,016 shares (7.62%). Executive and director group ownership is disclosed as 157,874 shares (2.10%). The filing also lists director nominees, director fees and various outstanding option grants with grant dates, strike prices and expiration dates.
Vivos Therapeutics, Inc. (VVOS) reported interim financial results reflecting recent acquisition activity and constrained liquidity. The company completed an acquisition (SCN) with total preliminary consideration of about $8.7 million, including $6.0 million cash, 607,287 restricted shares valued at $1.3 million and contingent earn‑out equity estimated at $1.4 million. Goodwill rose to $5.6 million and identifiable intangible assets of $1.9 million were recorded.
For the six months ended June 30, 2025, the company had revenues reported in the periods shown (examples: $3.8 million and $4.1 million in comparative periods shown), operating losses (e.g., $(4.9) million and $(1.9) million in shown periods) and an accumulated deficit of approximately $113.1 million. Cash and cash equivalents were about $4.4 million with total liabilities of approximately $21.5 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern absent additional financing. The company completed financing transactions in 2024–2025 including private placements and PIPE proceeds totaling several million dollars (including $2.7 million received in June 2025 and $3.7 million upon conversion of a bridge note).
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
